Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.

Wei-Cheng LinYi-Fang DingHan-Lin HsuJer-Hwa ChangKevin Sheng-Po YuanAlexander T H WuJyh-Ming ChowChia-Lun ChangShee-Uan ChenSzu-Yuan Wu

Published in: Cancer (2017)

Trimodality therapy may be beneficial for the survival of patients with advanced-stage (IIIA-IIIC) TESCC, and CCRT might be an alternative to surgery alone in these patients. Cancer 2017;123:3904-15. © 2017 American Cancer Society.

Keyphrases

papillary thyroid
locally advanced
end stage renal disease
squamous cell
ejection fraction
chronic kidney disease
minimally invasive
rectal cancer
prognostic factors
spinal cord
lymph node metastasis
stem cells
childhood cancer
mesenchymal stem cells
spinal cord injury
cell therapy